Orforglipron vs Survodutide
A side-by-side research comparison of Orforglipron and Survodutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Orforglipron | Survodutide |
|---|---|---|
| Full name | Orforglipron (Oral Non-Peptide GLP-1 Agonist) | Survodutide (Dual GLP-1/Glucagon Agonist) |
| Category | Weight Management | Weight Management |
| Status | Phase 3 Clinical Trial | Phase 3 Clinical Trial |
| Mechanism | Small molecule agonist of GLP-1 receptors that mimics native GLP-1 binding without requiring peptide structure. Achieves full receptor activation with standard oral bioavailability. | Activates GLP-1 receptors to reduce appetite while glucagon receptor activation increases hepatic fat oxidation, energy expenditure, and amino acid catabolism. |
| Molecular weight | ~550 Da | 4,500 Da (approximate) |
| Half-life | 25-60 hours | 5-7 days |
| Bioavailability | Moderate-High (oral) | High (SubQ) |
| Typical dose | 12-45 mg | 0.6-6.0 mg |
| Frequency | Once daily | Once weekly |
| Route | Oral | Subcutaneous |
Orforglipron reported benefits
- Oral administration (no injection)
- No fasting requirement
- Significant weight loss (8-14%)
- Small molecule stability
- Lower manufacturing cost potential
Survodutide reported benefits
- Significant weight loss (up to 19%)
- Liver fat reduction
- Increased energy expenditure
- MASH resolution potential
- Improved lipid profile
Related comparisons
Research and educational reference only. Not medical advice.